Biogen Idec Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. The filing also reports fourth-quarter results; it is an annual report, not a standalone quarterly filing. Unless noted, figures below are in U.S. dollars.
Business context
Biogen Idec is a biotechnology company focused on multiple sclerosis (MS), autoimmune and neurodegenerative diseases, and hemophilia. Its principal revenue drivers were AVONEX, TYSABRI and its collaboration economics for RITUXAN. Management highlighted the potential 2013 launches of TECFIDERA and long-lasting Factor VIII and Factor IX, subject to regulatory approval.
Financial performance
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Total revenue | $5,516.5 million | $5,048.6 million | +9.3% |
| Operating income | $1,855.8 million | $1,724.7 million | +7.6% |
| Net income attributable to Biogen Idec | $1,380.0 million | $1,234.4 million | +11.8% |
| Diluted EPS | $5.76 | $5.04 | +14.3% |
| Operating cash flow | $1,879.9 million | $1,727.7 million | +8.8% |
| Cash, cash equivalents and marketable securities | $3,742.4 million | $3,107.3 million | +20.4% |
| Total borrowings | $1,140.8 million | $1,064.1 million | +7.2% |
| Working capital | $1,586.9 million | $2,062.5 million | -23.1% |
Gross profit was $4,971.0 million, approximately 90.1% of revenue, versus $4,581.9 million, approximately 90.8%, in 2011. Operating margin was approximately 33.6%, versus 34.2%; net margin was approximately 25.0%, versus 24.4%. Cash and marketable securities exceeded borrowings by approximately $2.6 billion. Working capital declined primarily because the $450 million 6.0% Senior Notes due March 1, 2013 were classified as current.
Product revenue was $4,166.1 million (+8.6%); unconsolidated joint business revenue, primarily RITUXAN-related, was $1,137.9 million (+14.2%); other revenue was $212.5 million (-1.6%). AVONEX revenue rose 8.4% to $2,913.1 million, TYSABRI rose 5.2% to $1,135.9 million, and FAMPYRA revenue was $57.4 million versus $13.6 million in 2011. The filing reports RITUXAN collaboration revenue of $1,137.9 million, up 14.2%.
Fourth-quarter revenue was $1,417.9 million versus $1,326.7 million a year earlier. Net income attributable to Biogen Idec was $292.1 million versus $300.2 million, and diluted EPS was $1.23 versus $1.22.
Material changes and notable items
- Revenue growth was led by AVONEX, TYSABRI and the U.S. RITUXAN collaboration contribution. AVONEX U.S. revenue increased with price increases despite lower unit volume; TYSABRI U.S. revenue benefited from higher volume and pricing.
- Total costs and expenses rose 11.5% to $3,707.4 million, including R&D up 9.5% to $1,334.9 million and SG&A up 21.0% to $1,277.5 million. Management attributed much of the increase to development and commercial preparation for potential launches.
- Operating cash flow increased, while investing cash use was $950.3 million and financing cash use was $877.5 million. The company repurchased $984.7 million of shares and spent $254.5 million on property, plant and equipment.
- A $46.8 million gain was recorded from selling BENLYSTA royalty and other rights. The 2012 results also included $71.0 million of Isis collaboration upfront payments and $27.2 million of contingent-consideration fair-value expense.
- Quarter-four net income included a $30.0 million Isis R&D charge and a $29.0 million deferred-tax accounting correction. The company said the accumulated tax correction was not material.
- Biogen Idec discontinued dexpramipexole development for ALS after its Phase 3 trial missed primary and key secondary endpoints; it accrued $12.3 million for related commitments and cancellation costs.
Outlook, risks and contingencies
- No formal consolidated revenue or earnings guidance is provided in the supplied filing text. Management estimated that European pricing and cost-containment measures could reduce 2013 revenue by approximately $45 million to $60 million.
- TECFIDERA was under FDA review with a target decision date in late March 2013; management anticipated a U.S. launch in the second quarter of 2013 if approved. Factor IX’s U.S. application had been submitted; Factor VIII filing was planned for the first half of 2013. Peginterferon applications were planned by mid-2013.
- Key risks include dependence on three principal products, competition and potential biosimilars, clinical and regulatory uncertainty, and TYSABRI’s serious PML risk. The company also cited pricing and reimbursement pressure, foreign-exchange exposure, manufacturing and supply risks, and delayed European government receivables.
- At year-end, receivables from Italy, Portugal and Spain totaled $207.5 million; $17.6 million was classified as non-current. The company had deferred $62.7 million of 2012 Italian TYSABRI revenue amid a dispute with the Italian medicines agency over reimbursement limits.
- Material proceedings included the pending Hoechst arbitration damages decision affecting the Genentech collaboration, patent disputes, a Medicaid pricing-related False Claims Act case, and tax disputes. The filing does not provide a clear estimate of potential losses for several proceedings.
- Potential future collaboration milestone payments were up to approximately $1.5 billion, contingent on development, regulatory or commercial achievements; these were not recorded as liabilities because the milestones had not occurred. The $450 million senior notes mature in March 2013.
- The company stated that it had sufficient funds and expected operating cash flow to meet foreseeable requirements. The auditor gave an unqualified opinion on the financial statements and reported effective internal control over financial reporting.
Most important facts for investors to verify
- Whether TECFIDERA and the hemophilia candidates secured approvals, launched on schedule, and generated revenue consistent with launch expectations.
- Whether TYSABRI sales growth continued and whether PML cases or risk-management changes affected prescribing and revenue.
- Whether European pricing pressure, Italian TYSABRI revenue deferrals, and slow government collections altered revenue, cash conversion or credit-loss exposure.
- How the $450 million notes due March 2013 were repaid or refinanced, and how subsequent capital allocation compared with the 2012 share repurchases.
- Developments in the Hoechst arbitration, tax assessments, patent cases and other contingencies, including any change in estimated exposure.
- Whether contingent milestone obligations, capital spending and the Cambridge headquarters relocation produced material cash costs or charges beyond reported estimates.